Evidence Studies for Tea Tree

Total Page:16

File Type:pdf, Size:1020Kb

Evidence Studies for Tea Tree Evidence Studies for Tea Tree Oil The Benefi ts of Cleansing with FungaSoap® Evidence Authors & Journal Article Title Area Instructions J Hosp Infect (England), Nov 2000, Tea tree oil as an alternative topical Caelli M, Porteous J, Carson Anti Bacterial 46(3) p236-7 decolonization agent for methicillin-resistant CF, et al. Staphylococcus aureus. J Antimicrob Chemother (England), Time-kill studies of tea tree oils on clinical May J, Chan CH, King A, et al. May 2000, 45(5)p639-43 isolates. J Appl Microbiol (England), Jan 2000, The mode of antimicrobial action of the Cox SD, Mann CM, Markham 88(1) p170-5 essential oil of Melaleuca alternafolia (tea JL, et al. tree oil). Oral Microbiol Immunol (Denmark), Susceptibility of oral bacteria to Melaleuca Hammer KA, Dry L, Johnson Dec 2003, 18(6)p389-92 alternifolia (tea tree) oil in vitro. M, et al. J Microbial Methods (Netherlands), Leakage of K+ ions from Staphylococcus Hada T, Inoue Y, Shiraishi A, Jun 2003, 53(3)p309-12 aureus in response to tea tree oil. et al. Antimicrob Agents Chemother Mechanism of action of Melaleuca alternifolia Carson CF, Mee BJ, Riley TV (United States), June 2002, 46(6) (tea tree) oil on Staphylococcus aureus p1914-20 determined by time-kill, lysis, leakage, and saltll tolerance assays and dl electron microscopy. J Am Podiatr Med Assoc (United 1998 William J. Stickel Bronze Award. Concha JM, Moore LS, States), Oct 1998, 88(10) p489-92 Antifungal activity of Melaleuca Alternifolia Holloway WJ Anti Fungal (tea tree) oil against various pathogenic organisms. Antimicrob Agents Chemother In vitro activities of ketoconazole, econazole, Hammer KA, Carson CF, (United States), Feb 2000, 44(2) miconazole, and Melaleuca alternafolia (tea Riley TV p467-9 tree) oil against Malassezia species. J Antimicrob Chemother (England), In vitro and in vivo activity of tea tree oil Mondello F, De Bernardis F, May 2003, 51(5) p1223-9 against azole-susceptible and - resistent Girolamo A, et al. human pathogenic yeasts. Lett Appl Microbiol (England), 2003, Antimycotic activity of Melaleuca alternalfolia Oliva B, Piccirilli E, Ceddia T, 37(2) p185-7 essetial oil and its major components. et al. J Appl Microbiol (England), 2003, Antifungal activity of the components of Hammer KA, Carson CF, 95(4)p853-60 Melaleuca alternifolia (tea tree) oil. Riley TV J Am Acad Dermatol (United States), Treatment of dandruff with 5% tea tree oil Satchell AC, Saurajen A, Bell Dec 2002, 47(6)p852-5 shampoo. C, et al. Australas J Dermatol ((),gAustralia), Aug Treatment of interdiggpital tinea pedis with 25% % Satchell AC,,j, Saurajen A, Bell 2002, 43(3) p175-8 and 50% tea tree oil solution; a randomized, C, et al. placebo-controlled, blinded study. J Antimicrob Chemother (England), In vitro activity of Melaleuca alternifolia (tea Hammer KA, Carson CF, Aug 2002, 50(2) p195-9 tree) oil against dermatophytes and other Riley TV filamentous fungi. Schwelz Arch Tierhelikd Antifungal effect of Australian tea tree oil on Weseler A, Geiss HK, Saller (Switzerland), May 2002, 144(5) Malassezia pachydermatis isolated from R, et al. p215-21 canines suffering from cutaneous skin disease. Anti Infective J Pharm Pharmacol (England), Mar Inhibition of acetylcholinesterase by Tea Tree Mills C, Cleary BJ, Gilmer JF, Scabicide 2004, 56(3) p375-9 oil. et al. Arch Dermatol (United States), May Acaricidal activity of Melaleuca alterifloia (tea Walton SF, McKinnon M, 2004, 140(5) p563-6 tree) oil: in vitro sensitivity of sarcoptes Pizzutto S, et al. scabiei var hominis to terpinen-4-ol. Inflamm Res (Switzerland), Nov Terpinen-4-ol, the main component of the Hart PH, Brand C, Carson CF, Anti 2000, (49)11 p619-26 essential oil of Melaleuca alternifolia (tea tree et al. Inflammatory oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm Res (Switzerland), June Tea tree oil reduces histamine-induced Brand C, Townley SL, Finlay- 2002, 51(6)p283-9 oedema in murine ears. Jones JJ, et al. Inflamm Res (Switzerland), May Tea tree oil reduces the swelling associated Brand C, Grimbaldeston MA, 2002, 51(5) p236-44 with the efferent phase of a hypersensitivity Gamble JR, et al. response. Br J Dermatol (England), Dec 2002, Tea tree oil reduces histamine-induced skin Koh KJ, Pearce AL, 147(6)p1212-7 inflammation. Marshman G, et al. J Invest Dermitol (United States), Terpinen-4-ol, the main component of Calcabrini A, Stringaro A, Anti Neo Plastic Feb 2004, 122(2) p349-60 Melaleuca alternifolia (tea tree) oil inhibits the Toccacieli L, et al. in vitro growth of human melanoma cells. Pharmazie (Germany), Apr 2001, Antiviral activity of Austrailian tea tree oil and Schnitzier P, Schon K, Anti Viral 56(4) p343-7 eucalyptus oil against herpes simplex virus in Reichling J cell culture. J Antimicrob Chemother (England), Melaleuca alternifolia (tea tree) oil gel (6%) Carson CF, Ashton L, Dry L, Sep 2001, 48(3) p450-1 for the treatment of recurrent herpes labialis. et al. For more information contact: PediFix Footcare Products 310 Guinea Road Brewster, NY 10509 ® 1-800-424-5561 The Most Trusted Family in Footcare, Since 1885 visit: www.pedifi x.com.
Recommended publications
  • Antibiofilm Efficacy of Tea Tree Oil and of Its Main Component Terpinen-4-Ol Against Candida Albicans
    ORIGINAL RESEARCH Periodontics Antibiofilm efficacy of tea tree oil and of its main component terpinen-4-ol against Candida albicans Renata Serignoli Abstract: Candida infection is an important cause of morbidity FRANCISCONI(a) and mortality in immunocompromised patients. The increase in its Patricia Milagros Maquera incidence has been associated with resistance to antimicrobial therapy HUACHO(a) and biofilm formation. The aim of this study was to evaluate the Caroline Coradi TONON(a) efficacy of tea tree oil (TTO) and its main component – terpinen-4-ol – Ester Alves Ferreira BORDINI(a) against resistant Candida albicans strains (genotypes A and B) identified by molecular typing and against C. albicans ATCC 90028 and SC 5314 Marília Ferreira CORREIA(a) reference strains in planktonic and biofilm cultures. The minimum Janaína de Cássia Orlandi inhibitory concentration, minimum fungicidal concentration, and SARDI(b) rate of biofilm development were used to evaluate antifungal activity. Denise Madalena Palomari Results were obtained from analysis of the biofilm using the cell (a) SPOLIDORIO proliferation assay 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H- tetrazolium-5-carboxanilide (XTT) and confocal laser scanning (a) Universidade Estadual Paulista – Unesp, microscopy (CLSM). Terpinen-4-ol and TTO inhibited C. albicans School of Dentistry of Araraquara, Department of Physiology and Pathology, growth. CLSM confirmed that 17.92 mg/mL of TTO and 8.86 mg/mL Araraquara, SP, Brazil of terpinen-4-ol applied for 60 s (rinse simulation) interfered with (b) Universidade Estadual de Campinas – biofilm formation. Hence, this in vitro study revealed that natural Unicamp, School of Dentistry of Piracicaba, substances such as TTO and terpinen-4-ol present promising results Department of Physiological Sciences, for the treatment of oral candidiasis.
    [Show full text]
  • Antifungal Agents in Agriculture: Friends and Foes of Public Health
    biomolecules Review Antifungal Agents in Agriculture: Friends and Foes of Public Health Veronica Soares Brauer 1, Caroline Patini Rezende 1, Andre Moreira Pessoni 1, Renato Graciano De Paula 2 , Kanchugarakoppal S. Rangappa 3, Siddaiah Chandra Nayaka 4, Vijai Kumar Gupta 5,* and Fausto Almeida 1,* 1 Department of Biochemistry and Immunology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP 14049-900, Brazil; [email protected] (V.S.B.); [email protected] (C.P.R.); [email protected] (A.M.P.) 2 Department of Physiological Sciences, Health Sciences Centre, Federal University of Espirito Santo, Vitoria, ES 29047-105, Brazil; [email protected] 3 Department of Studies in Chemistry, University of Mysore, Manasagangotri, Mysore 570006, India; [email protected] 4 Department of Studies in Biotechnology, University of Mysore, Manasagangotri, Mysore 570006, India; [email protected] 5 Department of Chemistry and Biotechnology, ERA Chair of Green Chemistry, Tallinn University of Technology, 12618 Tallinn, Estonia * Correspondence: [email protected] (V.K.G.); [email protected] (F.A.) Received: 7 July 2019; Accepted: 19 September 2019; Published: 23 September 2019 Abstract: Fungal diseases have been underestimated worldwide but constitute a substantial threat to several plant and animal species as well as to public health. The increase in the global population has entailed an increase in the demand for agriculture in recent decades. Accordingly, there has been worldwide pressure to find means to improve the quality and productivity of agricultural crops. Antifungal agents have been widely used as an alternative for managing fungal diseases affecting several crops. However, the unregulated use of antifungals can jeopardize public health.
    [Show full text]
  • Systemic Antifungal Drug Use in Belgium—
    Received: 7 October 2018 | Revised: 28 March 2019 | Accepted: 14 March 2019 DOI: 10.1111/myc.12912 ORIGINAL ARTICLE Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe Berdieke Goemaere1 | Katrien Lagrou2,3* | Isabel Spriet4,5 | Marijke Hendrickx1 | Eline Vandael6 | Pierre Becker1 | Boudewijn Catry6,7 1BCCM/IHEM Fungal Collection, Service of Mycology and Aerobiology, Sciensano, Summary Brussels, Belgium Background: Reports on the consumption of systemic antifungal drugs on a national 2 Department of Microbiology and level are scarce although of high interest to compare trends and the associated epi- Immunology, KU Leuven, Leuven, Belgium 3Clinical Department of Laboratory demiology in other countries and to assess the need for antifungal stewardship Medicine, National Reference Centre for programmes. Mycosis, University Hospitals Leuven, Leuven, Belgium Objectives: To estimate patterns of Belgian inpatient and outpatient antifungal use 4Department of Pharmaceutical and and provide reference data for other countries. Pharmacological Sciences, KU Leuven, Methods: Consumption records of antifungals were collected in Belgian hospitals Leuven, Belgium between 2003 and 2016. Primary healthcare data were available for the azoles for 5Pharmacy Department, University Hospitals Leuven, Leuven, Belgium the period 2010-2016. 6 Healthcare‐Associated Infections and Results: The majority of the antifungal consumption resulted from prescriptions of Antimicrobial Resistance, Sciensano, Brussels, Belgium fluconazole and itraconazole in the ambulatory care while hospitals were responsible 7Faculty of Medicine, Université Libre de for only 6.4% of the total national consumption and echinocandin use was limited. Bruxelles (ULB), Brussels, Belgium The annual average antifungal consumption in hospitals decreased significantly by Correspondence nearly 25% between 2003 and 2016, due to a decrease solely in non-university hos- Berdieke Goemaere, Sciensano, Mycology pitals.
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Table 1Fatty Acid Compostion of Salvia Species*
    ORIGINAL ARTICLE Org. Commun. 7:4 (2014) 114-122 Some new azole type heterocyclic compounds as antifungal agents Mohammad Russell*1 and Mohammad Ikthair Hossain Soiket2 1Department of Textile Engineering, Bangladesh University of Business and Technology, Mirpur-2, Dhaka-1216, Bangladesh 2Department of Mechanical Engineering, Bangladesh University of Engineering and Technology, Polashi, Dhaka-1000, Bangladesh (Received July 2, 2013; Revised December 3, 2014; Accepted December 12, 2014) Abstract:Schiff’s base1-[(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)]ethanone thiosemicarbazone (compound 1A) wasprepared by condensation of 1-(2,4-difluorophenyl)-2- [1 (H)-1,2,4-triazol-1-yl]ethanone (1)with thiosemicarbazide. The compound 1A, on reaction with α-halogenoketones yielded 1-(2, 4-difluorophenyl)-2- [(1H)-1,2,4-triazol-1-yl] ethanone [2-[4-halogenophenyl] thiazolyl]hydrazone.Anti-fungal activity of all the compounds has been tested against four fungal organism:C. albicans, Colletotrichum spp., A. nigar and Fusarium spp. commonly responsible for fungal infections in Bangladesh. Keywords: Schiff’s bases; compound 1A; 1-(2,4-difluorophenyl)-2- [1 (H)-1,2,4-triazol-1-yl] ethanone (1); α- halogenoketones; 1-(2,4-difluorophenyl)-2-[(1H)-1,2,4-triazol-1-yl] ethanone [2-[4-halogenophenyl] thiazolyl] hydrazone;Anti-fungal activity.© 2014 ACG Publications. All rights reserved. 1. Introduction Triazole compounds are gettingincreasingattention because oftheir extensive medicinal applications as antimicrobial agents particularly in antifungal therapy, and a large number of predominant triazole drugs have been successfully developed and prevalently used for the treatment of various microbial infections for many years1-3. Azoles like fluconazole, itraconazole, voriconazole, and posaconazole are important antifungal drugs for the treatment of IFIs (invasive fungal infections), which continues to be a major cause ofmorbidity and mortality in immune compromised or in severely ill patients4.
    [Show full text]
  • Abnormal Vaginal Discharge: What Does and Does Not Work in Treating Underlying Causes
    AE_French.1104.final 10/18/04 11:03 AM Page 890 Applied Evidence N EW R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Abnormal vaginal discharge: What does and does not work in treating underlying causes Linda French, MD Michigan State University, East Lansing, Mich Jennifer Horton, DO Genesys Regional Medical Center Family Practice Residency, Grand Blanc, Mich Michelle Matousek, DO Henry Ford Health System, Detroit, Mich Practice recommendations part of this article, “Abnormal vaginal discharge: Using office diagnostic testing more effectively” ■ Treat bacterial vaginosis with oral or intravagi- (JFP 2004; 53[10]:805–814), abnormal discharge nal metronidazole or with clindamycin (SOR: is more likely to be bacterial vaginosis or no A); recurrences are common (SOR: C). pathogen at all. Potential delay in diagnosis and treatment of a sexually transmitted disease is ■ Oral and intravaginal imidazoles are also a concern. Increasing resistance of Candida equally effective in the treatment of sp. to imidazoles is associated with indiscriminate candidiasis (SOR: A); alternate therapies use of over-the-counter products. for resistant cases have been little studied. ■ Oral metronidazole is the standard ■ BACTERIAL VAGINOSIS therapy for trichomoniasis (SOR: A). The standard treatment for bacterial vaginosis Oral tinidazole, newly available in the (BV) has been oral metronidazole (Flagyl) 500 mg US in 2004, should be used in resistant twice daily for 5 to 7 days. Intravaginal 0.75% cases (SOR: B). metronidazole gel (MetroGel) has been shown to be as effective as oral metronidazole (SOR: A).1,2 Oral metronidazole can cause nausea and ntifungal medications for intravaginal use abdominal pain in some patients; vaginal treat- have been available in the United States ment may be preferable for them.
    [Show full text]
  • Echinocandins As Biotechnological Tools for Treating Candida Auris Infections
    Journal of Fungi Review Echinocandins as Biotechnological Tools for Treating Candida auris Infections 1,2, 1, 1,2 Elizabete de Souza Cândido y , Flávia Affonseca y, Marlon Henrique Cardoso and Octavio Luiz Franco 1,2,* 1 S-Inova Biotech, Programa de Pós Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande 79117900; Brazil; [email protected] (E.d.S.C.); flavia.aff[email protected] (F.A.); [email protected] (M.H.C.) 2 Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília, Brasília 70790160, Brazil * Correspondence: [email protected] These authors equally contributed for this work. y Received: 31 July 2020; Accepted: 9 September 2020; Published: 22 September 2020 Abstract: Candida auris has been reported in the past few years as an invasive fungal pathogen of high interest. Its recent emergence in healthcare-associated infections triggered the efforts of researchers worldwide, seeking additional alternatives to the use of traditional antifungals such as azoles. Lipopeptides, specially the echinocandins, have been reported as an effective approach to control pathogenic fungi. However, despite its efficiency against C. auris, some isolates presented echinocandin resistance. Thus, therapies focused on echinocandins’ synergism with other antifungal drugs were widely explored, representing a novel possibility for the treatment of C. auris infections. Keywords: lipopeptides; echinocandins; Candida auris; infections; antifungal drugs 1. Introduction Candidiasis is one of the most common causes of fungal infection on a global scale and includes both superficial and invasive infections. The major concern is associated with patients in intensive care units (ICU) with high mortality rates. There are several fungal species isolated in the clinical setting responsible for these infections.
    [Show full text]
  • Topical Salicylic Acid and Lactic Acid Microemulsion
    Organic and Medicinal Chemistry International Journal ISSN 2474-7610 Research Article Organic & Medicinal Chem IJ Volume 2 Issue 3 - May 2017 DOI: 10.19080/OMCIJ.2017.02.555587 Copyright © All rights are reserved by Maher Aljamal Topical Salicylic acid and Lactic acid Microemulsion Maher Aljamal1,2*, Ibrahim Kayali2 and Mohammad Abul-Haj2 1BeitJala Pharmaceutical Company / Research and Development department, Palestine 2Department of Chemistry, Palestine, Al- Quds university, Israel Submission: April 26, 2017; Published: May 02, 2017 *Corresponding author: Maher Aljamal, BeitJala Pharmaceutical Company / Research and Development department, Al- Quds university, Palestine, Tel: ; Email: Abstract Microemulsionsare used to solubilizing and improve an active pharmaceutical ingredientssolubility and permeability, such as those for topical absorption availability. The objective of this study was to prepare a microemulsion liquid composed of 12% salicylic acid and 4% of lactic acid using castor oil, Tween 80, propylene glycol, ethyl alcohol and purified water. Using the low energy emulsification technique; four andpseudo transparent/translucent ternary phase diagrams microemulsion. were constructed The Resultsand studied indicate for ata leastclear, 75thermodynamic days under a titrationmicroemulsion method liquid using obtainedpurified waterin each (with of the or without propylene glycol), each phase diagram was investigated at 25°C, 37°C and 45°C. The phases include conventional emulsion, viscous using low concentration of Tween 80. It was suggested that microemulsions of 12% Salicylic acid and 4% Lactic acid could be a suitable vehicleconstructed for topical phase treatment diagrams ofat psoriasis, all temperatures scaly patches, of study. ichthyoses, Using propylene dandruff, glycol corns, as calluses, a co-surfactant, and wartson lead the to handsmore orstable feet.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Heterocyclic Chemistrychemistry
    HeterocyclicHeterocyclic ChemistryChemistry Professor J. Stephen Clark Room C4-04 Email: [email protected] 2011 –2012 1 http://www.chem.gla.ac.uk/staff/stephenc/UndergraduateTeaching.html Recommended Reading • Heterocyclic Chemistry – J. A. Joule, K. Mills and G. F. Smith • Heterocyclic Chemistry (Oxford Primer Series) – T. Gilchrist • Aromatic Heterocyclic Chemistry – D. T. Davies 2 Course Summary Introduction • Definition of terms and classification of heterocycles • Functional group chemistry: imines, enamines, acetals, enols, and sulfur-containing groups Intermediates used for the construction of aromatic heterocycles • Synthesis of aromatic heterocycles • Carbon–heteroatom bond formation and choice of oxidation state • Examples of commonly used strategies for heterocycle synthesis Pyridines • General properties, electronic structure • Synthesis of pyridines • Electrophilic substitution of pyridines • Nucleophilic substitution of pyridines • Metallation of pyridines Pyridine derivatives • Structure and reactivity of oxy-pyridines, alkyl pyridines, pyridinium salts, and pyridine N-oxides Quinolines and isoquinolines • General properties and reactivity compared to pyridine • Electrophilic and nucleophilic substitution quinolines and isoquinolines 3 • General methods used for the synthesis of quinolines and isoquinolines Course Summary (cont) Five-membered aromatic heterocycles • General properties, structure and reactivity of pyrroles, furans and thiophenes • Methods and strategies for the synthesis of five-membered heteroaromatics
    [Show full text]
  • Antifungal and Antibiotic Powders
    ANTIFUNGAL AND ANTIBIOTIC POWDERS Antifungals: Econazole Powder, Ketoconazole Powder, Nyamyc (nystatin) Powder, Nystop (nystatin) Powder Antibiotics: Mupirocin Powder, Tobramycin Powder, Vancomycin Powder RATIONALE FOR INCLUSION IN PA PROGRAM Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Pharmacy powder products have the potential for misuse. Misuse of these powder products is quite common and it is important to inform patients about the possible complications due to overuse of these drugs. Regulatory Status FDA approved indication: Antifungal agents kill fungi or inhibit their growth. Antifungals that kill fungi are called fungicidal while those that inhibit their growth are called fungistatic. Antibiotics, or antimicrobials, are medications that destroy or slow down the growth of bacteria.
    [Show full text]
  • Azole-Induced Cell Wall Carbohydrate Patches Kill Aspergillus Fumigatus
    ARTICLE DOI: 10.1038/s41467-018-05497-7 OPEN Azole-induced cell wall carbohydrate patches kill Aspergillus fumigatus Bernadette Geißel1, Veronika Loiko1, Isabel Klugherz1, Zhaojun Zhu1, Nikola Wagener2, Oliver Kurzai3,4, Cees A.M.J.J. van den Hondel5 & Johannes Wagener1,3,4 Azole antifungals inhibit the fungal ergosterol biosynthesis pathway, resulting in either growth inhibition or killing of the pathogen, depending on the species. Here we report that 1234567890():,; azoles have an initial growth-inhibitory (fungistatic) activity against the pathogen Aspergillus fumigatus that can be separated from the succeeding fungicidal effects. At a later stage, the cell wall salvage system is induced. This correlates with successive cell integrity loss and death of hyphal compartments. Time-lapse fluorescence microscopy reveals excessive synthesis of cell wall carbohydrates at defined spots along the hyphae, leading to formation of membrane invaginations and eventually rupture of the plasma membrane. Inhibition of β-1,3- glucan synthesis reduces the formation of cell wall carbohydrate patches and delays cell integrity failure and fungal death. We propose that azole antifungals exert their fungicidal activity by triggering synthesis of cell wall carbohydrate patches that penetrate the plasma membrane, thereby killing the fungus. The elucidated mechanism may be potentially exploited as a novel approach for azole susceptibility testing. 1 Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Medizinische Fakultät, LMU München, Pettenkoferstraße 9a, 80336 Munich, Germany. 2 Zell- und Entwicklungsbiologie, Department Biologie II, LMU München, Großhaderner Straße 2, 82152 Planegg-Martinsried, Germany. 3 Institut für Hygiene und Mikrobiologie, Julius-Maximilians-Universität Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany.
    [Show full text]